$17.09+0.06 (+0.38%)
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States.
Burning Rock Biotech Limited in the Healthcare sector is trading at $17.09. The stock is currently 59% below its 52-week high of $41.72, remaining 2.0% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why BNR maintains its current momentum and trend strength. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Developm...
Brenntag (ETR:BNR) executives said fiscal 2025 played out against one of the most prolonged downturns in the chemical industry in decades, with market conditions deteriorating as the year progressed and volumes weakening notably in the second half. On the company’s full-year results call, management
Burning Rock Biotech (BNR) , a precision oncology company from China, has shown exceptional technical momentum and price appreciation. BNR has surged 405% over the past year, hitting a 2-year high on Wednesday. Despite strong technicals, BNR is a highly speculative and risky stock. Today’s Chart of the Day is...
The U.S. stock market has been navigating a period of volatility, with major indices such as the Dow Jones Industrial Average and the S&P 500 experiencing fluctuations amid geopolitical tensions and economic policy discussions. Despite these broader market challenges, penny stocks remain an intriguing area for investors, representing smaller or newer companies that can offer potential value when backed by strong financials. In this context, we explore three penny stocks that exhibit financial...